---
title: "Immunovant, Inc. (IMVT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/IMVT.US.md"
symbol: "IMVT.US"
name: "Immunovant, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T16:50:28.216Z"
locales:
  - [en](https://longbridge.com/en/quote/IMVT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/IMVT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/IMVT.US.md)
---

# Immunovant, Inc. (IMVT.US)

## Company Overview

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [immunovant.com](https://immunovant.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -14.31 | 481 | - | - | - |
| PB | 8.49 | 377 | 7.84 | 5.31 | 4.27 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-21T04:00:00.000Z

Total Analysts: **18**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 11 | 61% |
| Overweight | 2 | 11% |
| Hold | 5 | 28% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 33.45 |
| Highest Target | 66.00 |
| Lowest Target | 22.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/IMVT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/IMVT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/IMVT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/IMVT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**